External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification

Basit Öğe Kaydı
dc.contributor.authorArjona-Sanchez, A.
dc.contributor.authorMartinez-López, A.
dc.contributor.authorMoreno-Montilla, M.T.
dc.contributor.authorMulsow, J.
dc.contributor.authorLozano-Lominchar, P.
dc.contributor.authorMartínez-Torres, B.
dc.contributor.authorRau B.
dc.date.accessioned2024-05-19T14:34:28Z
dc.date.available2024-05-19T14:34:28Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ?15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification. Method: It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan–Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching. Results: After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP?15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP?15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated. Conclusion: the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients. © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncologyen_US
dc.identifier.doi10.1016/j.ejso.2023.03.206
dc.identifier.endpage1488en_US
dc.identifier.issn0748-7983
dc.identifier.issue8en_US
dc.identifier.pmid36935222en_US
dc.identifier.scopus2-s2.0-85150308268en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1481en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejso.2023.03.206
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4494
dc.identifier.volume49en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW.B. Saunders Ltden_US
dc.relation.ispartofEuropean Journal of Surgical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAntineoplastic Agenten_US
dc.subjectKi 67 Antigenen_US
dc.subjectKi 67 Antigenen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectArticleen_US
dc.subjectCancer Classificationen_US
dc.subjectCancer Patienten_US
dc.subjectCancer Survivalen_US
dc.subjectCell Densityen_US
dc.subjectCohort Analysisen_US
dc.subjectControlled Studyen_US
dc.subjectCytoreductive Surgeryen_US
dc.subjectDisease Free Survivalen_US
dc.subjectFemaleen_US
dc.subjectFollow Upen_US
dc.subjectHumanen_US
dc.subjectHuman Tissueen_US
dc.subjectHyperthermic İntraperitoneal Chemotherapyen_US
dc.subjectLabeling İndexen_US
dc.subjectMajor Clinical Studyen_US
dc.subjectMaleen_US
dc.subjectMedian Survival Timeen_US
dc.subjectMulticenter Studyen_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectOverall Survivalen_US
dc.subjectPeritoneum Pseudomyxomaen_US
dc.subjectPredictive Valueen_US
dc.subjectProliferation İndexen_US
dc.subjectProspective Studyen_US
dc.subjectReceiver Operating Characteristicen_US
dc.subjectSurvival Rateen_US
dc.subjectSystemic Therapyen_US
dc.subjectTissue Sectionen_US
dc.subjectValidation Processen_US
dc.subjectClinical Trialen_US
dc.subjectPathologyen_US
dc.subjectPeritoneum Pseudomyxomaen_US
dc.subjectPeritoneum Tumoren_US
dc.subjectPrognosisen_US
dc.subjectProportional Hazards Modelen_US
dc.subjectRetrospective Studyen_US
dc.subjectHumansen_US
dc.subjectKi-67 Antigenen_US
dc.subjectPeritoneal Neoplasmsen_US
dc.subjectPrognosisen_US
dc.subjectProportional Hazards Modelsen_US
dc.subjectPseudomyxoma Peritoneien_US
dc.subjectRetrospective Studiesen_US
dc.titleExternal multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classificationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu